Background: To evaluate quantitative and qualitative changes in sub-basal corneal nerves (SBN) via in vivo confocal microscopy in patients with Sjögren syndrome dry eye (SSDE) treated with topical cyclosporine A (CsA).
Methods: A clinical evaluation of dry eye, corneal sensation using Cochet-Bonnet esthesiometry and in vivo confocal microscopy analysis of the central cornea were performed prospectively at baseline for all patients, and after 6 months of treatment with CsA.
Main outcome measures: Density, number, reflectivity and tortuosity of SBN, dendritic cell (DC) density, esthesiometry, and dry eye signs and symptoms.
Results: Topical CsA 0.05% improved clinical signs and symptoms, and increased corneal sensitivity. Following treatment, SBN density was significantly increased (P < 0.0001) associated with a decreased in DC density (P < 0.0001). The increase in SBN density after treatment was positively correlated with baseline SBN density (R 2 = 0.33; P = 0.0008) and negatively correlated with baseline Ocular Surface Disease Index (R 2 = 0.28; P = 0.002), Oxford score (R 2 = 0.31; P = 0.002), and DC density (R 2 = 0.37; P = 0.0003).
Conclusions: Topical CsA led to an increase in corneal SBN density, improving clinical signs and symptoms of SSDE. Our results also suggest an improved response to treatment in patients with less initial nerve damage.
INTRODUCTION
Dry eye syndrome (DES) is one of the most frequently encountered afflictions in clinical ophthalmology, affecting 5-30% of patients over the age of 50. 1 DES is recognized as a disturbance of the lacrimal functional unit that comprises the lacrimal glands, the ocular surface and lids, and the sensory and motor nerves that link them. Sjögren's syndrome (SS), a chronic inflammatory autoimmune disease, is a major cause of severe dry eye syndrome.
SS may be primary, if isolated, or secondary to an autoimmune disease (e.g. rheumatoid arthritis, disseminated lupus erythematosus, or systemic sclerosis). 2 Inflammation has been clearly implicated in the pathophysiology of DES, and anti-inflammatory treatments are increasingly used in the management of patients with DES refractory to conventional treatment with artificial tears. Corneal nerves are also implicated, and patients with DES showed lower sub-basal nerve (SBN) density [3] [4] [5] , greater nerve tortuosity [3] [4] [5] [6] and a higher dendritic cell (DCs) density in the cornea [6] [7] [8] than healthy patients. 9, 10 In addition to their important sensory function, corneal nerves play a critical role delivering nutrient neuropeptides necessary for the proliferation and maintenance of corneal epithelial cells. 11, 12 Cyclosporine A (CsA), an immunosuppressant of the calcineurin inhibitor family, is used in inflammatory diseases of the ocular surface, with an inhibiting effect on the T cell-dependent immune response, and production of pro-inflammatory cytokines. [13] [14] [15] Clinical studies have demonstrated the efficacy of CsA 0.05% and 0.1% ophthalmic suspensions in improving the signs and symptoms of DES.
1,14-16 Liu and co-workers recently described the anti-inflammatory effect of CsA via an in vivo confocal microscopy (IVCM) based study: they demonstrated a significant decrease in corneal DC density following treatment with 0.5% CsA eye drops in patients with vernal keratoconjunctivitis. 17 Nevertheless, the effects of CsA eye drops on corneal innervation remain unclear. Several in vitro and in vivo experimental models have suggested that CsA may have a neurotrophic effect, stimulating the growth of cells in altered sciatic, facial or trigeminal nerves. [18] [19] [20] [21] [22] Similarly, clinical studies have shown that CsA may improve corneal sensitivity in patients treated for DES 23 or after LA-SIK refractive surgery. 24 Nonetheless, Namavari and colleagues have demonstrated in a mouse corneal transplant model that topical CsA slowed nerve growth and regeneration. 25 We used IVCM to analyze the quantitative and qualitative changes in the SBNs in the central cornea of patients treated with CsA 0.05% for Sjögren syndrome dry eye (SSDE) refractory to conventional treatment to determine its clinical effects.
METHODS Patients
This prospective, observational, non-randomized clinical study was performed at the Quinze-Vingts National Ophthalmology Hospital in Paris, France. Informed consent was obtained from each patient prior to inclusion in the study according to the tenets of the Declaration of Helsinki, and the study was approved by the Ethics Committee of the French Society of Ophthalmology (Institutional Review Board 00008855).
Thirty eyes of 30 patients with primary or secondary SSDE requiring treatment with CsA topical treatment were included between December 2013 and December 2014. Diagnosis of SS was made according to the Sjögren's International Collaborative Clinical Alliance (SICCA) criteria. 26 The inclusion criteria were: age ≥ 18 years; Schirmer test without anesthesia: <10 mm/5 min; tear break-up time (BUT) < 10 s; Oxford score 27 ≥ 1; presence of dry eye (DE) signs and symptoms despite conventional treatment (preservative free artificial tears during a 3 months period) justifying an initiation of topical CsA. Patients received CsA 0.05% (0.5 mg/mL) ophthalmic suspension twice daily, in accordance with international recommendations concerning the use of CsA eye drops to treat DES. 16, 28, 29 This treatment was delivered as a hospital preparation by the hospital pharmacy. The patients were allowed to continue their treatment with preservative-free artificial tears. Exclusion criteria were: presence of any other ocular disorder or systemic disease (history of eye trauma or surgery, ocular surface disease, systemic disease, diabetes and neuropathy) likely to interfere with the interpretation of the results; contact lens use; current or recent use of a systemic or topical treatment likely to affect tear secretion; use of topical cyclosporine or steroids during the 3 months preceding the study. Fifteen eyes of 15 healthy volunteers, age and gender matched, comprised the control group. These subjects had no symptoms and no eye disease, with normal results on biomicroscopic examination and ocular surface testing, and did not receive any treatment.
Data collection
Demographic data and medical history were obtained from the medical records. We used the Ocular Surface Disease Index (OSDI) and an evaluation of the frequency of instillation of artificial tears to assess the severity of symptoms. 30 All subjects subsequently underwent a complete examination of the ocular surface including, in the following order: Schirmer's I test, BUT, corneal and conjunctival staining using fluorescein dye, an evaluation of central corneal sensitivity (esthesiometry) and an IVCM analysis of the SBN and the DCs in the corneal center. Central corneal sensitivity was measured using a Cochet-Bonnet contact esthesiometer (Luneau Ophtalmologie, Paris, France). 31 All variables were evaluated at inclusion for all patients and after 6 months of treatment for the SSDE patients.
Confocal microscopy
In vivo confocal microscopy analysis was performed with the Heidelberg Retina Tomograph III with Rostock Corneal Module© (Heidelberg Engineering GmbH, Dossenheim, Germany). Acquired images consisted of 384 × 384 pixels over a 400 × 400 μm field of view. Manufacturer quoted transverse resolution and optical section thickness are 2 and 4 μm, respectively. The sub-basal nerve plexus images were defined as the first clear images of the nerves anterior to Bowman's layer. DC images were acquired at a depth of 35-60 microns just beneath the level of the basal epithelial layers. 7 DCs were morphologically identified as bright individual dendritiform structures differentiated from corneal nerves. For SBN and DCs, the three sharpest images were selected for analysis. All selected images were then anonymized and randomized by one investigator (OL). Another investigator (NB) carried out quantitative and qualitative analyses of these images using NEURON J software (National Institutes of Health, Bethesda, MD, USA) 32 for SBN, and IMAGE J software (National Institutes of Health, Bethesda, MD, USA) for DCs; the entire image (400 μm × 400 μm) was used for quantitative analyses. We analyzed the following variables for SBNs: density, number, reflectivity and tortuosity. 33, 34 Reflectivity and tortuosity were classified according to a validated semiquantitative scale. 33, 34 For DC analysis, we counted the number of DCs on each image and then calculated their density. Mean values for three images were analyzed. Definitions for all the variables analyzed by IVCM are provided in Table 1 .
Statistical analysis
One eye was randomly selected from each patient for statistical analysis. Quantitative variables were expressed as mean AE standard deviation (SD), and qualitative variables were expressed as percentages. For binary outcomes, the stratified Cochran chisquare test was used for intergroup comparisons of proportions. The Student's t-test for paired data was used to compare preoperative and postoperative continuous parameters. Measurements between groups were compared using independent sample t-test.
Pearson's correlation coefficient test was used to explore the relationship between various clinical and IVCM findings. Corrected P values < 0.05 were considered statistically significant. The statistical analysis was carried out with SPSS software for WIN-DOWS version 20.0 (SPSS, Inc., Chicago, IL, USA).
RESULTS

Population description before treatment
Thirty eyes of 30 patients were included in CsA 0.05% group. Fifteen healthy eyes of 15 volunteers comprised the control group, matched for age and gender. SSDE patients were significantly different from the controls for the following clinical and IVCM findings: Schirmer's test, BUT, Oxford score, OSDI, corneal sensitivity, nerve density and number, SBN tortuosity and DC density. The demographic, clinical and IVCM data are presented in Table 2 .
At inclusion, in SSDE patients, SBN and DC densities were correlated with several clinical tests: OSDI (r = À0.57, R 2 = 0.32, P = 0.001 and r = 0.70, R 2 = 0.49, P < 0.0001, respectively), Oxford test (r = À0.46, R 2 = 0.21, P = 0.009 and r = 0.79, R 2 = 0,62, P < 0.0001, respectively) and corneal sensitivity (r = 0.54, R 2 = 0.29, P = 0.002 and r = À0.51, R 2 = 0.26, P = 0.004, respectively). SBN density and number were strongly negatively correlated with DC density (r = À0.66, R 2 = 0.43, P < 0.0001 and r = À0.54, R 2 = 0.29, P = 0.002, respectively) ( Fig. 1) . SBN density was also found to be strongly positively correlated with the number of nerves (r = 0.63, R 2 = 0.39, P < 0.0001). Age was negatively correlated with number of nerves but not with SBN density (r = À0.52, R 2 = 0.27, P = 0.002 and r = À0.26, R 2 = 0.06, P = 0.12, respectively). There was no significant correlation between SBN density and reflectivity (r = À0.022, R 2 = 0.0005, P = 0.90) or between nerve density and tortuosity (r = À0.25, R 2 = 0.06, P = 0.18).
Corneal sensitivity was negatively correlated with age (r = À0.52, R 2 = 0.27, P = 0.003), Oxford score (r = À0.53, R 2 = 0.28, P = 0.003) and DC density (r = À0.51, R 2 = 0.26, P = 0.003), and was positively correlated with SBN density (r = 0.54, R 2 = 0.29, P = 0.002) and number (r = 0.61, R 2 = 0.37, P < 0.001). (Figs 2,3) . 0.05% CsA treated patients still differed from the control group for all the variables except tortuosity after treatment. The changes in clinical and IVCM findings after 6 months of treatment are shown in Table 2 . The principal adverse effect of the treatment was a burning sensation at instillation, reported in seven patients of the 0.05% CsA group (23.3%). No serious secondary adverse effects were observed.
Correlation between change in nerve density and baseline clinical and in vivo confocal microscopy findings
In SSDE patients, the variation in corneal nerve density under treatment was negatively correlated with initial OSDI (r 2 = 0.28; P = 0.002), Oxford score (r 2 = 0.31; P = 0.001) and DC density (r 2 = 0.37; P = 0.0003), and positively correlated with initial SBN density and number (r 2 = 0.33; P = 0.0008 and r 2 = 0.19; P = 0.016, respectively). Results of correlations are presented in Table 3 .
DISCUSSION
After 6 months of treatment, with 0.05% CsA, patients with SSDE showed a significant decrease in clinical signs and symptoms of DE with an 
Dry eye syndrome and changes in corneal innervation
In vivo confocal microscopy analyses revealed significant abnormalities in corneal innervation in SSDE patients before treatment with lower SBN density and more tortuous nerves compared with normals. Such features have been reported in previous studies, together with the correlation between nerve rarefaction and clinical severity of DE. [3] [4] [5] [33] [34] [35] [36] These findings suggest that direct nerve damage occurs in DE, regardless of its etiology, the damage being correlated to the severity of the ocular surface lesions and responsible for corneal sensitivity alterations. These changes probably begin with nerve endings within the superficial epithelium directly exposed to ocular surface disturbances. However, the resolution of in vivo confocal microscopes (approximately 2 μm) is currently insufficient to evaluate such changes.
Dry eye syndrome and corneal inflammation
Consistent with previous studies, we observed a higher density of DCs in the corneal center correlating with DE severity (OSDI and Oxford scores). 6, 37 Thus, DC density and the immune responses of patients seem to be directly linked to the severity of this condition. Ocular surface dryness is a sign of injury, with apoptosis and an increase in the concentrations of certain pro-inflammatory mediators (TNF-α, IL-1 and MMP9) known to modulate the maturation and migration of DCs. Thus, once activated, the limbal DCs migrate towards the corneal center, initiating a vicious circle of inflammation underlying DES. 8, 37 Therapeutic effect of CsA on dry eye syndrome As in studies evaluating the clinical efficacy of topical CsA for DES 1, [14] [15] [16] 23 , we observed that treatment with 0.05% CsA for 6 months led to a significant improvement in the signs and symptoms of DES. As observed by Toker and co-workers 23 , we found that this improvement was associated with an increase in corneal sensitivity.
Topical CsA treatment also led to a significant decrease in the density of corneal DCs, providing direct evidence of a decrease in local tissue inflammation. This result is consistent with those of Liu and colleagues, who reported similar improvements in patients with vernal keratoconjunctivitis treated with 0.5% CsA. 17 Our study demonstrated changes in corneal innervation during treatment with CsA eye drops. Following 6 months of treatment, patients receiving CsA presented a significant increase in SBN density and a decrease in SBN tortuosity suggesting corneal nerve regeneration.
The increase in nerve density was positively correlated with nerve density and negatively correlated with OSDI, Oxford score and DC density before treatment. Thus, the patients with less damage at the initiation of treatment displayed the greatest increase in nerve density under CsA treatment. This result suggests that the response to treatment might be better if treatment were initiated earlier, before advanced nerve damage has occurred. Similarly, Kheirkhah and co-workers showed, in 60 patients with DE due to meibomian gland dysfunction treated with artificial tears or topical corticosteroids for 1 month, that a significant improvement in corneal fluorescein staining and symptoms of DE was observed only in the subgroup of patients with near-normal SBN density before initiation of treatment. 38 A close relation between response to treatment and baseline confocal evaluation was showed by Villani and colleagues about DCs: in 50 patients with DE treated with topical corticosteroids for 1 month, the greater improvement (DC density and OSDI decreases) under treatment was observed in patients with the lower baseline DC density. 39 Such effects may be the result of several factors. Firstly, potentially increased trophic support of corneal nerves delivering neuropeptides to epithelial cells may help epithelial healing during therapy, thereby improving the Oxford score. Secondly, patients with greater SBN density may probably better report a subjective improvement. Nerve regeneration may be less likely in cases where extensive nerve destruction has already occurred, 40 potentially accounting for our finding that the patients displaying the greatest nerve changes were those with the lowest nerve damages before treatment.
Mode of action of topical cyclosporine A on corneal innervation
The modes of action of CsA on corneal nerves remain undetermined. Several mechanisms have been described. CsA may act directly on nerve cells. Studies on several in vivo and in vitro models suggested that CsA and its analogs (immunophilin ligands) have direct neurotrophic effects on damaged nerve cells. [18] [19] [20] Lee and co-workers also showed that CsA induced the secretion of nerve growth factor (NGF) by cultured epithelial cells, via an intracellular signaling pathway involving NFAT5 and p38. 21 However, CsA also has powerful anti-inflammatory properties, and this is probably its primary mode of action. Applied as eye drops, CsA decreases the number of activated T lymphocytes, the presentation of inflammation markers (HLA-DR and CD11a) and the expression of proinflammatory cytokines, such as IL-6. 41, 42 In our study, it significantly decreased the density of corneal DCs, providing direct evidence of the decrease in antigen presenting cells and local inflammation, and leading to an improvement of epithelial lesions (as demonstrated by the decrease in Oxford score) and corneal sensitivity. These improvements in corneal sensitivity and the lower level of damage to nerve endings enable a decreased release of neuropeptides involved in neurogenic inflammation and enhance the reflex arc, thereby stimulating the blinking reflex and tear secretion. 40 Thus, by interrupting the vicious circle of inflammation in DE, CsA may re-establish favorable conditions for corneal nerve regeneration.
Before treatment, nerve density and number were inversely correlated with DC density. Thus, higher levels of corneal inflammation were associated with greater nerve loss. Cruzat and co-workers reported a similar correlation in patients with infectious keratitis. 43 These results suggest that excessive inflammation may have deleterious effects on innervation. They also highlight the interconnections between the nervous and immune systems and the ways in which they can influence each other. 44 Some neuropeptides, such as calcitonin gene-related peptide, 45 substance P 46 and vasoactive intestinal peptide 47 seem to have immunomodulatory effects on the components of the immune reaction. In DE, nerve damages might prevent the nervous system from playing its immunomodulatory role.
In the other hand, some studies have shown that inflammation may favor nerve regeneration. After corneal SBN destruction following corneal injury, nerve regeneration requires T-cell activation, an influx of polynuclear neutrophils and platelets, and the secretion of IL-17 and VEGF. 48 , 49 Namavari and co-workers showed that 6 weeks of treatment with 0.05% CsA eye drops significantly slowed the influx of inflammatory cells, cytokine segregation and nerve regeneration in a mouse model of lamellar keratoplasty. 25 These results demonstrate that, in an acute context of corneal nerve transection uncomplicated by excessive inflammation, an influx of inflammatory cells is required to promote the initiation of nerve regeneration. The immunomodulatory effect of CsA would therefore be deleterious in such conditions. By contrast, in a context of DE, topical CsA can promote progression towards a normalization of innervation, by controlling the inflammatory reaction.
Mains limitations of this study are the lack of placebo-controlled group and the lack of a 6 months later repeated confocal examination in healthy controls. However, we attributed the improvement in ocular surface to the effect of cyclosporine A, which has been demonstrated by several randomized versus placebo studies. Moreover, the patients in this study received standard artificial tear therapy before enrollment, and all were unresponsive.
To conclude, in patients with moderate to severe SSDE, treatment for 6 months with 0.05% CsA eye drops led to an improvement in the clinical signs and symptoms of DES, an increase in corneal sensitivity, and an increase in SBN density. The increase in nerve density was positively correlated with initial SBN density and negatively correlated with initial DC density. Thus, early treatment with CsA eye drops may result in a better response to treatment. The increase in sub-basal nerves density promoted by CsA probably results from its effect of breaking the vicious cycle of inflammation in DES. The possibility of a direct neurotrophic effect cannot be excluded, but further studies are required to determine its exact nature.
